Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $2.15. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -111.16%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.63 per share when it actually produced earnings of $1.72, delivering a surprise of +5.52%.Over the last four quarters, ...